J&J U.S. PHARMACEUTICAL SALES CLIMB 15.6% TO $496 MIL. IN FIRST QUARTER; SCHERING CLARITIN SALES ARE $130 MIL. IN FIRST NINE MONTHS ON U.S. MARKET
Johnson & Johnson's domestic pharmaceutical sales rose 15.6% in the first three months of 1994 to $496 mil., the company reported April 28. The growth rate surpassed the 1993 first quarter increase of 11.1% for U.S. prescription drug sales.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth